Abstract
This study evaluated the outcome of first-line antiretroviral therapy among 35 Ghanaians with occult HBV/HIV co-infection, comparing them over 2 years to 120 patients with HBsAg+ HBV/HIV co-infection and 230 patients without HBV co-infection. Increases in CD4 cell count and BMI were similar, whereas elevations of hepatic transaminases were more frequent in both the occult HBV and HBsAg+ patients. Occult HBV/HIV co-infection appears not to impact adversely on response to antiretroviral therapy in Ghana.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anti-HIV Agents / therapeutic use*
-
Body Mass Index
-
CD4 Lymphocyte Count
-
Coinfection
-
Disease Progression
-
Female
-
Ghana / epidemiology
-
HIV Infections / drug therapy*
-
HIV Infections / epidemiology
-
HIV Infections / immunology
-
Hepatitis B / drug therapy*
-
Hepatitis B / epidemiology
-
Hepatitis B / immunology
-
Hepatitis B Surface Antigens / blood
-
Humans
-
Lamivudine / therapeutic use*
-
Male
-
Prevalence
-
Reverse Transcriptase Inhibitors / therapeutic use*
-
Treatment Outcome
-
Viral Load / drug effects
Substances
-
Anti-HIV Agents
-
Hepatitis B Surface Antigens
-
Reverse Transcriptase Inhibitors
-
Lamivudine